XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting - Schedule of Segment Revenue and Operating Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Revenues $ 717.4 $ 666.2
Adjusted EBITDA 97.5 90.1
Reconciliation of Adjusted EBITDA:    
Income (loss) before income taxes 28.7 (0.4)
Net income attributable to non-controlling interests (36.7) (26.1)
Interest expense, net 47.3 46.8
Depreciation and amortization 33.7 33.7
Equity-based compensation expense 4.9 4.2
Transaction, integration and acquisition costs 18.9 12.8
Net loss on disposals, consolidations and deconsolidations 1.5 10.5
Litigation settlements and regulatory change impact (1.2) 8.0
Undesignated derivative activity 0.0 0.6
Other 0.4 0.0
Transaction and integration costs 17.4 12.5
Start-up costs 1.5 0.3
(Loss) gain on litigation settlement 1.8 (3.0)
Other litigation costs 0.6 0.6
Additional interest expense for Florida LOP regulation change   4.4
Operating Segments | Surgical Facility Services    
Segment Reporting Information [Line Items]    
Revenues 692.7 649.0
Adjusted EBITDA 126.7 118.8
Operating Segments | Ancillary Services    
Segment Reporting Information [Line Items]    
Revenues 24.7 17.2
Adjusted EBITDA (1.4) (1.4)
All other    
Segment Reporting Information [Line Items]    
Adjusted EBITDA $ (27.8) $ (27.3)